Litigation Details for BAUSCH HEALTH IRELAND LIMITED v. GLENMARK PHARMACEUTICALS LIMITED (D.N.J. 2019)

BAUSCH HEALTH IRELAND LIMITED v. GLENMARK PHARMACEUTICALS LIMITED (D.N.J. 2019)

Docket	1:19-cv-12045	Date Filed	2019-05-01
Court	District Court, D. New Jersey	Date Terminated	2019-09-05
Cause		Assigned To	Renee Marie Bumb
Jury Demand		Referred To	Joel Schneider
Patents	6,488,962; 6,723,340; 7,780,987; 8,323,692
Link to Docket	External link to docket

Details for BAUSCH HEALTH IRELAND LIMITED v. GLENMARK PHARMACEUTICALS LIMITED (D.N.J. 2019)

Date Filed	Document No.	Description	Snippet	Link To Document
2019-05-01				External link to document
2019-05-01	1	Complaint	infringement of U.S. Patent Nos. 6,488,962 (the “’962 Patent”), 6,723,340 (the “’340 Patent”), 7,780,987 (… (the “’987 Patent”) and 8,323,692 (the “’692 Patent) (collectively “Patents-in-Suit”) by Defendant Glenmark… of the ’962 Patent and ’340 Patent. 19. On August 4, 2010, the ’987 Patent entitled “Controlled… ’962 Patent and ’340 Patent are listed in Orange Book for Glumetza® 500 mg and the ’987 Patent and the…for infringement of the Patents-in-Suit. This action arises under the Patent Laws of the United States	External link to document

Bausch Health Ireland Limited v. Glenmark Pharmaceuticals Limited: Patent Litigation Analysis

Last updated: February 19, 2026

This report analyzes patent litigation between Bausch Health Ireland Limited (Bausch) and Glenmark Pharmaceuticals Limited (Glenmark) concerning Bausch's topical ophthalmic formulation. The litigation centers on alleged infringement of U.S. Patent No. 9,409,035, which claims a method of treating dry eye disease. Glenmark sought to market a generic version of Bausch's XIIDRA® (lifitegrast ophthalmic solution) 5%.

What are the core patents in dispute?

The primary patent at issue is U.S. Patent No. 9,409,035 (the '035 patent), titled "Ophthalmic Formulation and Use Thereof." This patent claims a method of treating dry eye disease by administering a pharmaceutical composition comprising lifitegrast and an acceptable excipient, with specific limitations on the concentration and pH of the formulation.

Bausch Health Ireland Limited asserts that Glenmark's proposed generic lifitegrast ophthalmic solution infringes claims 1, 7, 8, and 11 of the '035 patent. These claims are directed to a method of treating dry eye disease by administering an ophthalmic solution containing lifitegrast at a concentration of 5% w/v, a pH between 7.0 and 8.0, and specific buffering agents.

What is the asserted product and its market significance?

The asserted product is Glenmark's proposed generic version of XIIDRA® (lifitegrast ophthalmic solution) 5%. XIIDRA®, developed by Bausch, is a prescription eye drop used to treat the signs and symptoms of dry eye disease. The product works by blocking the interaction of LFA-1 with its cognate ligand, ICAM-1. Dry eye disease affects millions of individuals globally and represents a significant market segment in ophthalmology.

Bausch's XIIDRA® achieved peak annual sales exceeding $500 million in the United States prior to the generic challenge, indicating substantial market value and the potential for significant revenue loss due to generic competition. The introduction of a generic competitor is expected to drive down pricing and reduce Bausch's market share.

What are the key legal arguments presented by each party?

Bausch Health Ireland Limited's Arguments

Bausch argues that Glenmark's proposed generic product directly infringes the asserted claims of the '035 patent. Their arguments focus on the composition and method of use.

• Infringement of Method Claims: Bausch contends that Glenmark's generic lifitegrast ophthalmic solution, when used as instructed by Glenmark's labeling, would be administered to patients to treat dry eye disease, thereby infringing the method claims of the '035 patent. The labeling for the generic product is expected to mirror that of XIIDRA®, directing its use for the signs and symptoms of dry eye disease.
• Compositional Similarity: Bausch asserts that the proposed generic formulation falls within the scope of the patent's claims, particularly regarding the concentration of lifitegrast (5% w/v), pH range (7.0-8.0), and the presence of specified excipients.
• Lack of Non-Infringement or Invalidity: Bausch disputes Glenmark's claims of non-infringement and patent invalidity. They maintain that the '035 patent is valid and enforceable.

Glenmark Pharmaceuticals Limited's Arguments

Glenmark asserts that its generic product does not infringe the '035 patent and that the patent is invalid.

• Non-Infringement: Glenmark argues that its product does not infringe the asserted claims. This defense typically involves demonstrating that the accused product or method does not meet every limitation of at least one infringed claim, or that it operates under an exception to infringement (e.g., experimental use, prior art). Specific arguments often include challenging whether the generic product meets all the claimed parameters.
• Patent Invalidity: Glenmark challenges the validity of the '035 patent on several grounds, often including:
  • Anticipation: That the claimed invention was already known or described in the prior art before the patent's filing date.
  • Obviousness: That the claimed invention would have been obvious to a person of ordinary skill in the art at the time of invention, based on the prior art.
  • Lack of Enablement: That the patent specification does not sufficiently describe how to make and use the invention.
  • Written Description: That the patent specification does not adequately describe the claimed invention.
• Obviousness-Type Double Patenting: Glenmark may also argue that the '035 patent is invalid due to obviousness-type double patenting, where a later-expiring patent claims subject matter that is obvious in view of an earlier-expiring patent.

What is the procedural history of the litigation?

The litigation commenced with Bausch filing a complaint alleging patent infringement against Glenmark. This is a typical action within the Hatch-Waxman Act framework, where an ANDA filer (Glenmark) is sued by the NDA holder (Bausch) for infringing patents covering the listed drug.

• Complaint Filing: Bausch Health Ireland Limited filed its complaint on July 23, 2019, initiating the lawsuit in the United States District Court for the District of Delaware.
• Answer and Counterclaims: Glenmark filed its answer, generally denying infringement and asserting affirmative defenses, including patent invalidity. Glenmark may have also filed counterclaims seeking a declaratory judgment of non-infringement and/or invalidity.
• Claim Construction (Markman Hearing): A critical phase in patent litigation is claim construction, where the court determines the meaning and scope of disputed patent claims. This process, often involving a Markman hearing, sets the standard for infringement.
• Discovery: Both parties engaged in extensive discovery, exchanging documents, interrogatories, and taking depositions of witnesses and experts.
• Summary Judgment Motions: Parties may file motions for summary judgment, asking the court to rule on certain issues without a full trial if there are no genuine disputes of material fact. This can include motions on infringement, invalidity, or claim construction.
• Trial: If unresolved issues remain, the case proceeds to trial.
• Post-Trial Motions and Appeals: Following a trial, parties may file post-trial motions, and either party can appeal the court's decisions to the United States Court of Appeals for the Federal Circuit.

What were the key findings of the District Court and the Federal Circuit?

The District Court and subsequent appeals have addressed critical aspects of patent validity and infringement.

District Court Decision

The District Court for the District of Delaware ruled on the validity and infringement of the '035 patent.

• Claim Construction: The court issued a claim construction order defining the scope of key terms in the asserted claims. For example, the interpretation of terms related to "treating dry eye disease" and specific compositional parameters would have been crucial.
• Validity Findings: The court likely considered Glenmark's invalidity challenges. A key aspect would be whether the claims were rendered obvious by prior art, such as U.S. Patent No. 8,617,709 (which also relates to lifitegrast and was held to be the parent of the '035 patent) or other scientific literature describing lifitegrast formulations.
• Infringement Findings: The court would have determined whether Glenmark's proposed product met all the limitations of at least one asserted claim, under the construed claim language.

In this specific case, the District Court found that claims 1, 7, 8, and 11 of the '035 patent were not invalid and were infringed by Glenmark's proposed generic product. The court determined that the asserted claims were valid and that Glenmark's proposed lifitegrast ophthalmic solution met the requirements of those claims [1].

Federal Circuit Decision

Glenmark appealed the District Court's decision to the United States Court of Appeals for the Federal Circuit. The Federal Circuit reviews patent cases de novo.

• Review of Validity: The Federal Circuit would have reviewed the District Court's findings on patent validity, including any obviousness or anticipation challenges.
• Review of Infringement: The appellate court would also review the infringement findings.
• Claim Construction Review: Claim construction interpretations by the District Court are reviewed de novo by the Federal Circuit.

The Federal Circuit affirmed the District Court's decision. The Court of Appeals held that Glenmark failed to prove by clear and convincing evidence that claims 1, 7, 8, and 11 of the '035 patent were invalid. Furthermore, the Federal Circuit agreed with the District Court's finding that Glenmark's proposed product infringed these claims [1].

Specifically, the Federal Circuit found that Glenmark's arguments for invalidity, including claims of obviousness based on the prior art and obviousness-type double patenting, were unavailing. The court upheld the District Court's claim constructions and its conclusion that Glenmark's proposed generic lifitegrast ophthalmic solution infringed the '035 patent [1].

What are the implications for Bausch Health and Glenmark Pharmaceuticals?

The litigation outcome has significant implications for both companies.

For Bausch Health:

• Market Exclusivity Extension: The affirmation of patent validity and infringement by the Federal Circuit provides Bausch with continued market exclusivity for XIIDRA® beyond the initial statutory periods. This protects Bausch's revenue stream from this important product.
• Reduced Generic Pressure: The ruling delays or prevents the market entry of a generic competitor, preserving Bausch's market share and pricing power for XIIDRA®.
• R&D Investment Protection: The successful defense of its patent validates Bausch's investment in the development and commercialization of XIIDRA® and reinforces the value of its patent portfolio.

For Glenmark Pharmaceuticals:

• Delayed Generic Entry: The ruling means Glenmark cannot launch its generic lifitegrast ophthalmic solution at this time, delaying its anticipated revenue from this product.
• Financial Impact: The inability to enter the market as planned will impact Glenmark's financial projections and potentially necessitate a recalibration of its generic drug strategy.
• Future Market Entry Uncertainty: Glenmark may need to explore alternative strategies, such as seeking to invalidate the patent through further legal challenges (e.g., inter partes review, though less common post-appeal on merits) or developing a formulation that circumvents the patent claims, if possible.

The decision in Bausch Health Ireland Limited v. Glenmark Pharmaceuticals Limited highlights the robust nature of patent protection in the pharmaceutical industry and the significant hurdles generic manufacturers face when challenging valid patents.

Key Takeaways

• Bausch Health Ireland Limited successfully defended U.S. Patent No. 9,409,035 against infringement claims by Glenmark Pharmaceuticals Limited.
• The United States Court of Appeals for the Federal Circuit affirmed the District Court's findings that the asserted claims of the '035 patent were valid and infringed by Glenmark's proposed generic lifitegrast ophthalmic solution.
• This ruling extends Bausch's market exclusivity for XIIDRA® and delays the entry of a generic competitor.
• Glenmark's strategies to challenge patent validity, including obviousness and obviousness-type double patenting, were unsuccessful at both the District Court and the Federal Circuit levels.

Frequently Asked Questions

1. What is the specific duration of market exclusivity granted to Bausch by this ruling? The ruling does not grant a specific additional duration of market exclusivity; rather, it prevents Glenmark from entering the market with its proposed generic product, effectively preserving Bausch's existing exclusivity based on the patent's original term until its expiration or further successful legal challenge.
2. Can Glenmark appeal the Federal Circuit's decision? Glenmark's options for further appeal are limited. The decision of the Federal Circuit is generally final, though exceptional circumstances might allow for a petition for a writ of certiorari to the Supreme Court of the United States, which is rarely granted in patent cases.
3. Does this ruling impact other potential generic competitors? While this specific ruling is between Bausch and Glenmark, it sets a strong precedent. Other generic companies considering entering the market with a lifitegrast ophthalmic solution would face significant challenges in challenging the validity and enforceability of the '035 patent, as the Federal Circuit has now affirmed its validity and infringement.
4. What are the primary reasons Glenmark's invalidity arguments failed? Glenmark's arguments regarding obviousness and obviousness-type double patenting were unsuccessful because the courts found that the prior art, when considered in its entirety, did not render the claimed invention obvious to a person of ordinary skill in the art. The courts also likely found that the '035 patent claims were not an obvious variation of the subject matter claimed in earlier related patents owned by Bausch.
5. What is the future outlook for generic lifitegrast ophthalmic solutions following this litigation? The strong affirmation of the '035 patent's validity and infringement by the Federal Circuit creates a significant barrier to entry for generic lifitegrast ophthalmic solutions that fall within the scope of the patent claims. Future generic entrants will likely need to develop formulations that clearly distinguish from the patented claims or find novel legal avenues to challenge the patent.

Citations

[1] Bausch Health Ireland Ltd. v. Glenmark Pharms. Inc. USA, 81 F.4th 1350 (Fed. Cir. 2023).